^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Qibeian (iparomlimab/tuvonralimab)

    i
    Other names: PSB205 , PSB-205, PSB 205 , Anti-PD-1/CTLA-4 MabPair, QL1706, PBS-103/PBS-105, QL 1706, QL-1706
    Company:
    Qilu Pharma, Sound Biologics
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    22h
    Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Lenvima (lenvatinib) • Inlyta (axitinib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3d
    A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer. (clinicaltrials.gov)
    P2, N=104, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P2 trial
    |
    carboplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    3d
    Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=290, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    cisplatin • carboplatin • Qibeian (iparomlimab/tuvonralimab)
    7d
    TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Fudan University
    New trial • IO biomarker
    |
    Qibeian (iparomlimab/tuvonralimab)
    8d
    Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer (clinicaltrials.gov)
    P2, N=29, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Lenvima (lenvatinib) • oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    11d
    SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=89, Not yet recruiting, Fujian Cancer Hospital
    New P2 trial
    |
    Jiataile (sacituzumab tirumotecan) • Qibeian (iparomlimab/tuvonralimab)
    11d
    QLC5508-201: A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=444, Recruiting, Qilu Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    cisplatin • carboplatin • paclitaxel • 5-fluorouracil • oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • MHB088C
    11d
    QLMA-IIT-CC-001: Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC (clinicaltrials.gov)
    P2, N=30, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • Qibeian (iparomlimab/tuvonralimab)
    18d
    Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer (clinicaltrials.gov)
    P2, N=188, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    carboplatin • docetaxel • Perjeta (pertuzumab) • Qibeian (iparomlimab/tuvonralimab)
    18d
    A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC (clinicaltrials.gov)
    P1, N=30, Recruiting, Xijing Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carboplatin • albumin-bound paclitaxel • cyclophosphamide • Qibeian (iparomlimab/tuvonralimab) • Pinorubin (pirarubicin)
    23d
    QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=45, Recruiting, Sun Yat-sen University | Initiation date: Jun 2025 --> Sep 2025
    Trial initiation date
    |
    Qibeian (iparomlimab/tuvonralimab)
    24d
    Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    cisplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)